Aurum sponsors Yissum's lipophilic drug trials
This article was originally published in Scrip
Executive Summary
Yissum Research Development, an Israeli technology transfer company, has signed an agreement with Aurum Ventures MKI for the development of a nanotechnology controlled- release drug delivery platform that increases the bioavailability of orally administered lipophilic drugs.